Memo Therapeutics AG, a Basel, Switzerland-based innovator in the field of antibody discovery and human immune repertoire analysis, closed a CHF 5.0m Series A2 financing round.
The round included new investors Schroder Adveq, investiere.ch and existing investors Redalpine Venture Partners, Zurich Cantonal Bank and other private investors.
The company intends to use the proceeds to further develop the proprietary MemoMABTM technology and to progress its antibody candidates in the fields of immuno-oncology and infectious diseases towards clinical trials.
Led by Chief Executive Officer Dr. Christoph Esslinger, Memo Therapeutics is a spin-off company of ETH Zurich whose proprietary platform allows users to create an authentic copy of whole antibody repertoires from humans and animals in recombinant form. Human antibody repertoires permit the identification of protective antibodies and their targets by comparison of different patient populations (e.g. responders vs. non-responders).
In addition, the ability to work with whole antibody repertoires increases the probability of success in finding antibodies against difficult targets, such as GPCRs, ion channels, CD3 and others.